Rituximab Biosimilar - Research Grade
Product Specifications
Background
Product Name Alternative
MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7
UniProt
P11836
Host
Humanized
Reactivity
Human
Target
CD20
Isotype
IgG1 κ
Sequence
https://www.imgt.org/mAb-DB/
Purification Method
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Concentration
1.0 - 5.0 mg/mL
Endotoxin
≤ 1.0 EU/mg as determined by the LAL method
Purity
>95% by SDS-PAGE and HPLC
Buffer
ICH3001-100ml ICH3002-100ml ICH3003-100ml
References & Citations
Narsimhan et al. Mobile Affinity Selection Chromatography Analysis of Therapeutic Monoclonal Antibodies. Analytical Chemistry
Shipping Conditions
Blue ice
Storage Conditions
Specificity
Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Rituximab.
Formulation
Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free.
Isotype Control
Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
RCHY1 Recombinant Antibody, FITC Conjugated
MDR1 (Multi Drug Resistance Protein 1, ABC20, ATP Binding Cassette Subfamily B (MDR/TAPC) Member 1, ABCB1, CD243, CLCS, GP170, P-Glycoprotein, P-gp, P Glycoprotein 1, PGY1) (APC)
MDR1 (Multi Drug Resistance Protein 1, ABC20, ATP Binding Cassette Subfamily B (MDR/TAPC) Member 1, ABCB1, CD243, CLCS, GP170, P-Glycoprotein, P-gp, P Glycoprotein 1, PGY1) (APC)